AAM
DNA icon

Areion Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Areion Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$4.4M Buy
+9,491
New +$4.62M 56.26% 1

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
SIG
Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
TAM
Telemark Asset Management Boston, Massachusetts $1.38B AUM 71.45% 1-Year Est. Return

Areion Asset Management's DNA Position: Q3 2021 in Review

Areion Asset Management opened a new position in Ginkgo Bioworks (DNA) in Q3 2021: 9,491 shares worth $4.4M. The stake represents 56.26% of the portfolio and ranks #1 among its holdings.

125 funds tracked by Wall St. Rank hold DNA as of Q3 2021.

  • Areion Asset Management held 9,491 shares of Ginkgo Bioworks worth $4.4M as of Q3 2021.
  • Ginkgo Bioworks was a new Areion Asset Management position in Q3 2021.
  • Ginkgo Bioworks made up 56.26% of Areion Asset Management's portfolio in Q3 2021, its #1 holding.
  • 125 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2021.

Based on Areion Asset Management's 13F filing for Q3 2021, filed 20 Oct 2021.